Pharmacological studies imply that inhibition of both COX-2 and mPGES-1 during obstruction may be effective as a therapeutic strategy to treat motility dysfunction during BO, and as a prophylactic strategy to prevent long-term motility dysfunction occurring after obstruction is resolved. This evidence concerns the gene PTGS2 and bronchiolitis obliterans syndrome.